# First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

> **NCT03798535** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1156 (actual)

## Conditions studied

- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03798535
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2024-07-16
- **Final completion:** 2024-07-16
- **Target enrollment:** 1156 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798535, "First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03798535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*